key: cord-1006334-5id2br8s
authors: Wu, Jun; Hu, Zhongjie; Wang, Liu; Tan, Yuanqing; Hou, Wei; Li, Zhongwen; Gao, Tingting; Fan, Jiaqi; Guo, Baojie; Dai, Huaping; Li, Wei; Hao, Jie; Jin, Ronghua; Hu, Baoyang
title: First case of COVID‐19 infused with hESC derived immunity‐ and matrix‐regulatory cells
date: 2020-10-26
journal: Cell Prolif
DOI: 10.1111/cpr.12943
sha: 80bbc623d58afa92df7fd8d2acc92c431908c510
doc_id: 1006334
cord_uid: 5id2br8s

nan

To the Editor, Acute lung injury (ALI) and the inflammatory cytokine storm cause considerable amount of deaths in the COVID-19 pandemic. 1

Currently, very limited therapeutic options are available for the COVID-19-induced ALI. In our preclinical experiments, 3 we found that a single intravenous transfusion of immunity-and matrix-regulatory cells (IMRCs), derived from fully differentiated human embryonic stem cells, could safely treat ALI by rapidly modulating the inflammation induced by pulmonary cell death. 3 Encouraged by this result, as part of an expanded access programme, we pilot-tested GMP-grade IMRC transfusion as a compassionate treatment in a severely ill COVID-19 patient who was diagnosed with ALI.

A 44-year-old male patient from Wuhan was admitted on 23 January 2020, presenting with a 6-day history of fever and cough.

The physical examination revealed a fever of 37.9°C, blood pressure of 120/61 mm Hg, pulse rate of 80 beats per minute, respiratory rate of 21 breaths per minute and blood oxygen saturation 

Beijing Youan Hospital

World Health Organization. Pneumonia of unknown cause reported to WHO China Office

World Health Organization. Public Health Emergency of International Concern declared

Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis

Additional supporting information may be found online in the Supporting Information section